Reports from the asco 2026 event are being highlighted, with a focus on immunotherapy. Some outlets are compiling lists of notable posts from the event, though the number and specific focus of these lists vary. One report indicates that post-surgery nivolumab did not improve disease-free survival over best supportive care in resected nsclc.